What is Octave Bioscience?
Octave Bioscience, Inc. is a pioneering healthcare technology firm dedicated to transforming the management of neurodegenerative diseases. At the core of its value proposition is the MSDA Test, the first multi-analyte blood test specifically engineered to monitor multiple sclerosis disease activity with high precision. By providing clinicians and patients with granular, personalized data, Octave Bioscience bridges the gap between traditional clinical observation and objective biological measurement. Through a strategic partnership with Quest Diagnostics, the company has successfully scaled its reach, ensuring that its diagnostic insights are accessible to healthcare providers nationwide, thereby facilitating more informed, data-driven treatment decisions for complex neurological conditions.
How much funding has Octave Bioscience raised?
Octave Bioscience has raised a total of $129M across 5 funding rounds:
Angel/Seed
$2.5M
Series A
$14M
Series B
$62M
Debt
$15.5M
Series C
$35M
Angel/Seed (2017): $2.5M, investors not publicly disclosed
Series A (2018): $14M led by Echo Health Ventures, Section 32, and BlueCross BlueShield Venture Partners
Series B (2023): $62M supported by Northpond Ventures LLC, Echo Health Ventures LLC, Section 32, Casdin Capital , LLC, The Blue Venture Fund, and Deerfield Communications Inc
Series C (2025): $35M featuring Hikma Ventures, Novartis, Northpond Ventures, S32, Casdin Capital, Byers Capital, The Blue Venture Fund, Valhalla Foundation, Intermountain West Joint Venture, and Merck Global Health Innovation Fund
Debt (2025): $15.5M backed by Silicon Valley Bank
Key Investors in Octave Bioscience
Section 32
S32 is a venture capital firm that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of scientific advancement.
Echo Health Ventures
Echo Health Ventures is a strategic venture capital firm focused on investing in and growing innovative healthcare companies committed to systemic transformation.
BlueCross BlueShield Venture Partners
BlueCross BlueShield Venture Partners manages significant capital to invest in emerging companies of strategic relevance to Blue Cross and Blue Shield plans.
What's next for Octave Bioscience?
With the successful closure of its latest financing round, Octave Bioscience is well-positioned to accelerate its clinical research initiatives and expand the utility of its diagnostic platform. The company is expected to leverage this capital to deepen its integration within the broader healthcare ecosystem, potentially exploring new therapeutic areas beyond multiple sclerosis. As the firm moves into a more mature operational phase, the focus will likely shift toward scaling its commercial infrastructure and enhancing its data analytics capabilities to further empower providers in the rapidly evolving landscape of precision medicine.
See full Octave Bioscience company page
